| 2025-12-11 |
详情>>
股本变动：
变动后总股本203851.48万股
|
| 2025-10-29 |
详情>>
业绩披露：
2025年三季报(累计)每股收益1.25英镑,归母净利润50.80亿英镑,同比去年增长135.08%
|
| 2025-10-29 |
财报披露：
美东时间 2025-10-29 盘前发布财报
|
| 2025-07-30 |
详情>>
业绩披露：
2025年中报每股收益0.75英镑,归母净利润30.67亿英镑,同比去年增长38.22%
|
| 2025-04-30 |
详情>>
业绩披露：
2025年一季报每股收益0.40英镑,归母净利润16.24亿英镑,同比去年增长55.26%
|
| 2025-03-03 |
详情>>
业绩披露：
2022年年报每股收益3.71英镑,归母净利润151.61亿英镑,同比去年增长245.75%
|
| 2025-03-03 |
详情>>
业绩披露：
2024年年报每股收益0.63英镑,归母净利润25.75亿英镑,同比去年增长-47.75%
|
| 2024-10-30 |
详情>>
业绩披露：
2024年三季报(累计)每股收益0.53英镑,归母净利润21.61亿英镑,同比去年增长-52.8%
|
| 2024-10-10 |
复牌提示：
2024-10-09 12:45:37 停牌，复牌日期 2024-10-09 13:10:58
|
| 2024-07-31 |
详情>>
业绩披露：
2024年中报每股收益0.55英镑,归母净利润22.19亿英镑,同比去年增长-28.74%
|
| 2024-05-01 |
详情>>
业绩披露：
2024年一季报每股收益0.26英镑,归母净利润10.46亿英镑,同比去年增长-29.8%
|
| 2024-03-25 |
股东大会：
将于2024-05-08召开股东大会
|
| 2024-03-25 |
股东大会：
将于2024-05-08召开股东大会
|
| 2024-03-05 |
详情>>
业绩披露：
2023年年报每股收益1.22英镑,归母净利润49.28亿英镑,同比去年增长-67.5%
|
| 2023-11-01 |
详情>>
业绩披露：
2023年三季报(累计)每股收益1.13英镑,归母净利润45.78亿英镑,同比去年增长-65.99%
|
| 2022-07-18 |
详情>>
拆分方案：
每5.0000合并分成4.0000股
|
| 2022-06-01 |
股东大会：
将于2022-07-06召开股东大会
会议内容 ▼▲
- 1.upon the recommendation and conditional on the approval of the directors of the Company (the “Directors”) and at such time and date as the Directors may determine prior to the ordinary shares (the “Haleon Shares”) of Haleon plc (“Haleon”) being admitted to the premium listing segment of the Official List of the Financial Conduct Authority and to trading on the main market for listed securities of the London Stock Exchange (“Admission”), an interim dividend in specie by the Company equal to the aggregate book value of the Company’s interest in the GSKCHH A Ordinary Shares of GlaxoSmithKline Consumer Healthcare Holdings Limited be and is hereby declared payable to holders of ordinary shares of the Company (“GSK Shares”) on the register of members of the Company at 6 p.m. on Friday 15 July 2022 (UK time) (or, such other time or date as the directors of the Company may determine) (the “Record Time”) (excluding the Company in respect of treasury shares) (each such holder being a “Qualifying Shareholder”), such dividend to be satisfied by the transfer prior to Admission by the Company to Haleon of the GSKCHH A Ordinary Shares in consideration for which Haleon has agreed to allot and issue Haleon Shares, effective prior to Admission and credited as fully paid, to such shareholders in the proportion of one Haleon Share for each GSK Share held by such Qualifying Shareholder (excluding the Company in respect of treasury shares) (save that, in respect of the four initial shareholders in Haleon (each of whom is, and will at the Record Time continue to be, a shareholder in the Company), the number of Haleon Shares to be allotted and issued to each of them will be reduced by the number of Haleon Shares already held by them at the Record Time) so that immediately prior to Admission all holders of GSK Shares (excluding the Company in respect of treasury shares) will hold one Haleon Share for each GSK Share held at the Record Time;
2.the Demerger (as defined and summarised in the circular sent to shareholders on Wednesday 1 June 2022 (the “Circular”)) is hereby approved for the purposes of Chapter 10 of the Listing Rules of the Financial Conduct Authority made under section 73A(1) of the Financial Services and Markets Act 2000 of the United Kingdom, as amended, and generally;
3.each and any of the directors of the Company be and is hereby authorised to conclude and implement the Demerger and to do or procure to be done all such acts and things on behalf of the Company and each of its subsidiaries as they may, in their discretion, consider necessary or expedient for the purpose of giving effect to the Demerger with such amendments, modifications, variations or revisions thereto as are not of a material nature;
4.subject to the passing of the Related Party Transactions Resolution, prior to the New GSK Shares (as defined below) being admitted to the premium listing segment of the Official List of the Financial Conduct Authority and to trading on the main market for listed securities of the London Stock Exchange, the Company and its Directors be authorised to:
4.1(a) consolidate each of the ordinary shares of ￡0.25 each in the capital of the Company (the “Existing GSK Shares”) into one or more (such number being at the discretion of the Directors) ordinary shares in the capital of the Company (such share or shares being “intermediate share(s)”), and (b) immediately after such consolidation, sub-divide the intermediate share(s) into new ordinary shares in the capital of the Company of such nominal value as the Directors may determine, such shares having the same rights and being subject to the same rights and being subject to the same restrictions (save as to nominal value) as the Existing GSK Shares in the capital of the Company as set out in the Company’s Articles of Association (the “New GSK Shares”); or
4.2(a) sub-divide each of the Existing GSK Shares into such number of ordinary shares in the capital of the Company as the Directors may determine (such shares being “intermediate shares”); and (b) immediately after such sub-division, consolidate the intermediate shares into such number of new ordinary shares in the capital of the Company of such nominal value as the Directors may determine, such shares having the same rights and being subject to the same restrictions (save as to nominal value) as the Existing GSK Shares in the capital of the Company as set out in the Company’s Articles of Association (the “New GSK Shares”);
4.3the record date for any such consolidation and/or sub-division shall be 8 p.m. on Monday 18 July 2022 or such other time and date that the Directors may determine;
4.4the Directors shall have discretion to make any arrangements which they consider necessary, appropriate or expedient: (a) to deal with fractions, rounding or other practical problems or matters which may result from any such consolidation and/or sub-division; or (b) for the purpose of giving effect to any such consolidation and/or sub-division;
4.5in particular and without prejudice to the general discretion of the Directors under the paragraph above, no shareholder shall be entitled to a fraction of a New GSK Share and where any such consolidation and/or sub-division would have resulted in any shareholder being entitled to a fraction of a New GSK Share, such fraction shall, so faras possible, be aggregated with the fractions of a New GSK Share (if any) to which other shareholders of the Company would be similarly so entitled and the Directors be and are hereby authorised to sell (or appoint any other person to sell) on behalf of the relevant shareholders to any person all the New GSK Shares representing such fractions in the open market at the price prevailing at the time of sale to any person(s), and to distribute the proceeds of sale (net of expenses) in due proportion among the relevant shareholders who would otherwise have been entitled to the fractions so sold, save that any fraction of a penny (or equivalent) which would otherwise be payable shall be rounded down to the nearest penny (and in order to implement the provisions of this paragraph, any Director (or any person appointed by the Directors) shall be and is hereby authorised to execute one or more instrument(s) of transfer in respect of such New GSK Shares on behalf of the relevant shareholder(s) and to do all acts and things the Directors consider necessary or desirable to effect the transfer of such new ordinary shares to any buyer of such New GSK Shares).
|
| 2022-06-01 |
股东大会：
将于2022-07-06召开股东大会
会议内容 ▼▲
- 1.upon the recommendation and conditional on the approval of the directors of the Company (the “Directors”) and at such time and date as the Directors may determine prior to the ordinary shares (the “Haleon Shares”) of Haleon plc (“Haleon”) being admitted to the premium listing segment of the Official List of the Financial Conduct Authority and to trading on the main market for listed securities of the London Stock Exchange (“Admission”), an interim dividend in specie by the Company equal to the aggregate book value of the Company’s interest in the GSKCHH A Ordinary Shares of GlaxoSmithKline Consumer Healthcare Holdings Limited be and is hereby declared payable to holders of ordinary shares of the Company (“GSK Shares”) on the register of members of the Company at 6 p.m. on Friday 15 July 2022 (UK time) (or, such other time or date as the directors of the Company may determine) (the “Record Time”) (excluding the Company in respect of treasury shares) (each such holder being a “Qualifying Shareholder”), such dividend to be satisfied by the transfer prior to Admission by the Company to Haleon of the GSKCHH A Ordinary Shares in consideration for which Haleon has agreed to allot and issue Haleon Shares, effective prior to Admission and credited as fully paid, to such shareholders in the proportion of one Haleon Share for each GSK Share held by such Qualifying Shareholder (excluding the Company in respect of treasury shares) (save that, in respect of the four initial shareholders in Haleon (each of whom is, and will at the Record Time continue to be, a shareholder in the Company), the number of Haleon Shares to be allotted and issued to each of them will be reduced by the number of Haleon Shares already held by them at the Record Time) so that immediately prior to Admission all holders of GSK Shares (excluding the Company in respect of treasury shares) will hold one Haleon Share for each GSK Share held at the Record Time;
2.the Demerger (as defined and summarised in the circular sent to shareholders on Wednesday 1 June 2022 (the “Circular”)) is hereby approved for the purposes of Chapter 10 of the Listing Rules of the Financial Conduct Authority made under section 73A(1) of the Financial Services and Markets Act 2000 of the United Kingdom, as amended, and generally;
3.each and any of the directors of the Company be and is hereby authorised to conclude and implement the Demerger and to do or procure to be done all such acts and things on behalf of the Company and each of its subsidiaries as they may, in their discretion, consider necessary or expedient for the purpose of giving effect to the Demerger with such amendments, modifications, variations or revisions thereto as are not of a material nature;
4.subject to the passing of the Related Party Transactions Resolution, prior to the New GSK Shares (as defined below) being admitted to the premium listing segment of the Official List of the Financial Conduct Authority and to trading on the main market for listed securities of the London Stock Exchange, the Company and its Directors be authorised to:
4.1(a) consolidate each of the ordinary shares of ￡0.25 each in the capital of the Company (the “Existing GSK Shares”) into one or more (such number being at the discretion of the Directors) ordinary shares in the capital of the Company (such share or shares being “intermediate share(s)”), and (b) immediately after such consolidation, sub-divide the intermediate share(s) into new ordinary shares in the capital of the Company of such nominal value as the Directors may determine, such shares having the same rights and being subject to the same rights and being subject to the same restrictions (save as to nominal value) as the Existing GSK Shares in the capital of the Company as set out in the Company’s Articles of Association (the “New GSK Shares”); or
4.2(a) sub-divide each of the Existing GSK Shares into such number of ordinary shares in the capital of the Company as the Directors may determine (such shares being “intermediate shares”); and (b) immediately after such sub-division, consolidate the intermediate shares into such number of new ordinary shares in the capital of the Company of such nominal value as the Directors may determine, such shares having the same rights and being subject to the same restrictions (save as to nominal value) as the Existing GSK Shares in the capital of the Company as set out in the Company’s Articles of Association (the “New GSK Shares”);
4.3the record date for any such consolidation and/or sub-division shall be 8 p.m. on Monday 18 July 2022 or such other time and date that the Directors may determine;
4.4the Directors shall have discretion to make any arrangements which they consider necessary, appropriate or expedient: (a) to deal with fractions, rounding or other practical problems or matters which may result from any such consolidation and/or sub-division; or (b) for the purpose of giving effect to any such consolidation and/or sub-division;
4.5in particular and without prejudice to the general discretion of the Directors under the paragraph above, no shareholder shall be entitled to a fraction of a New GSK Share and where any such consolidation and/or sub-division would have resulted in any shareholder being entitled to a fraction of a New GSK Share, such fraction shall, so faras possible, be aggregated with the fractions of a New GSK Share (if any) to which other shareholders of the Company would be similarly so entitled and the Directors be and are hereby authorised to sell (or appoint any other person to sell) on behalf of the relevant shareholders to any person all the New GSK Shares representing such fractions in the open market at the price prevailing at the time of sale to any person(s), and to distribute the proceeds of sale (net of expenses) in due proportion among the relevant shareholders who would otherwise have been entitled to the fractions so sold, save that any fraction of a penny (or equivalent) which would otherwise be payable shall be rounded down to the nearest penny (and in order to implement the provisions of this paragraph, any Director (or any person appointed by the Directors) shall be and is hereby authorised to execute one or more instrument(s) of transfer in respect of such New GSK Shares on behalf of the relevant shareholder(s) and to do all acts and things the Directors consider necessary or desirable to effect the transfer of such new ordinary shares to any buyer of such New GSK Shares).
|
| 2022-03-28 |
股东大会：
将于2022-05-04召开股东大会
|
| 2022-03-28 |
股东大会：
将于2022-05-04召开股东大会
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-03-30 |
股东大会：
将于2021-05-05召开股东大会
|
| 2021-03-30 |
股东大会：
将于2021-05-05召开股东大会
|
| 2020-05-06 |
股东大会：
将于2020-05-06召开股东大会
会议内容 ▼▲
- 1.Receive and adopt the 2019 Annual Report
2.Approve the Annual report on remuneration
3.To approve the Remuneration policy
4.Election of Sir Jonathan Symonds
5.Election of Charles Bancroft
6.Re-election of Emma Walmsley
7.Re-election of Vindi Banga
8.Re-election of Dr Hal Barron
9.Re-election of Dr Hal Barron
10.Re-election of Lynn Elsenhans
11.Re-election of Dr Laurie Glimcher
12.Re-election of Dr Jesse Goodman
13.Re-election of Judy Lewent
14.Re-election of Iain Mackay
15.Re-election of Urs Rohner
16.Re-appointment of the auditor
17.Remuneration of auditor
18.Authority for the company to make donations to political organisations and incur political expenditure
19.Authority to allot shares
20.Disapplication of pre-emption rights - general power
21.Disapplication of pre-emption rights - in connection with an acquisition or specified capital investment
22.Authority for the company to purchase its own shares
23.Exemption from statement of senior statutory auditor's name
24.Authority for reduced notice of a general meeting other than an AGM
|
| 2020-05-06 |
股东大会：
将于2020-05-06召开股东大会
会议内容 ▼▲
- 1.Receive and adopt the 2019 Annual Report
2.Approve the Annual report on remuneration
3.To approve the Remuneration policy
4.Election of Sir Jonathan Symonds
5.Election of Charles Bancroft
6.Re-election of Emma Walmsley
7.Re-election of Vindi Banga
8.Re-election of Dr Hal Barron
9.Re-election of Dr Hal Barron
10.Re-election of Lynn Elsenhans
11.Re-election of Dr Laurie Glimcher
12.Re-election of Dr Jesse Goodman
13.Re-election of Judy Lewent
14.Re-election of Iain Mackay
15.Re-election of Urs Rohner
16.Re-appointment of the auditor
17.Remuneration of auditor
18.Authority for the company to make donations to political organisations and incur political expenditure
19.Authority to allot shares
20.Disapplication of pre-emption rights - general power
21.Disapplication of pre-emption rights - in connection with an acquisition or specified capital investment
22.Authority for the company to purchase its own shares
23.Exemption from statement of senior statutory auditor's name
24.Authority for reduced notice of a general meeting other than an AGM
|
| 2020-02-05 |
除权日：
美东时间 2020-02-20 每股派息0.59美元
|
| 2019-04-02 |
股东大会：
将于2019-05-08召开股东大会
会议内容 ▼▲
- 1.THAT the Transaction (as defined and summarised in the circular sent to shareholders on 2 April 2019 (the “Circular”)) to be implemented in accordance with the terms and conditions contained in the Stock and Asset Purchase Agreement (as defined and summarised in the Circular) entered into between the Company, GlaxoSmithKline Consumer Healthcare Holdings Limited and Pfizer Inc. and the associated and ancillary agreements and arrangements relating thereto or to be entered into pursuant thereto, be and are hereby approved for the purposes of Chapter 11 of the Listing Rules of the Financial Conduct Authority, and that the Directors of the Company (or a duly authorised committee thereof) be and are hereby authorised to:
a.take all such steps, execute all such agreements and make all such arrangements as may seem to them necessary, expedient or desirable for the purpose of giving effect to, or otherwise in connection with, the Transaction and/or the associated and ancillary agreements and arrangements relating thereto or to be entered into pursuant thereto;
b.agree and make such modifications, variations, revisions, waivers or amendments in relation to any of the foregoing (provided that such modifications, variations, revisions, waivers or amendments are not material) as they may in their absolute discretion think necessary, expedient or desirable.
|
| 2019-04-02 |
股东大会：
将于2019-05-08召开股东大会
会议内容 ▼▲
- 1.THAT the Transaction (as defined and summarised in the circular sent to shareholders on 2 April 2019 (the “Circular”)) to be implemented in accordance with the terms and conditions contained in the Stock and Asset Purchase Agreement (as defined and summarised in the Circular) entered into between the Company, GlaxoSmithKline Consumer Healthcare Holdings Limited and Pfizer Inc. and the associated and ancillary agreements and arrangements relating thereto or to be entered into pursuant thereto, be and are hereby approved for the purposes of Chapter 11 of the Listing Rules of the Financial Conduct Authority, and that the Directors of the Company (or a duly authorised committee thereof) be and are hereby authorised to:
a.take all such steps, execute all such agreements and make all such arrangements as may seem to them necessary, expedient or desirable for the purpose of giving effect to, or otherwise in connection with, the Transaction and/or the associated and ancillary agreements and arrangements relating thereto or to be entered into pursuant thereto;
b.agree and make such modifications, variations, revisions, waivers or amendments in relation to any of the foregoing (provided that such modifications, variations, revisions, waivers or amendments are not material) as they may in their absolute discretion think necessary, expedient or desirable.
|
| 2019-02-07 |
除权日：
美东时间 2019-02-21 每股派息0.59美元
|
| 2018-11-01 |
除权日：
美东时间 2018-11-15 每股派息0.48美元
|
| 2018-07-25 |
除权日：
美东时间 2018-08-09 每股派息0.49美元
|
| 2018-03-29 |
股东大会：
将于2018-05-03召开股东大会
|
| 2018-03-29 |
股东大会：
将于2018-05-03召开股东大会
|
| 2018-02-07 |
除权日：
美东时间 2018-02-22 每股派息0.63美元
|
| 2017-10-25 |
除权日：
美东时间 2017-11-09 每股派息0.49美元
|
| 2017-07-26 |
除权日：
美东时间 2017-08-09 每股派息0.49美元
|
| 2017-04-26 |
除权日：
美东时间 2017-05-10 每股派息0.48美元
|
| 2017-03-30 |
股东大会：
将于2017-05-04召开股东大会
|
| 2017-03-30 |
股东大会：
将于2017-05-04召开股东大会
|
| 2017-02-08 |
除权日：
美东时间 2017-02-22 每股派息0.57美元
|
| 2016-10-26 |
除权日：
美东时间 2016-11-02 每股派息0.46美元
|
| 2016-07-27 |
除权日：
美东时间 2016-08-10 每股派息0.50美元
|
| 2016-04-28 |
除权日：
美东时间 2016-05-11 每股派息0.55美元
|
| 2016-03-30 |
股东大会：
将于2016-05-05召开股东大会
|
| 2016-03-30 |
股东大会：
将于2016-05-05召开股东大会
|
| 2016-02-03 |
除权日：
美东时间 2016-02-17 每股派息1.25美元
|
| 2015-10-28 |
除权日：
美东时间 2015-11-10 每股派息0.58美元
|
| 2015-07-29 |
除权日：
美东时间 2015-08-12 每股派息0.59美元
|
| 2015-05-06 |
除权日：
美东时间 2015-05-13 每股派息0.58美元
|
| 2015-03-25 |
股东大会：
将于2015-05-07召开股东大会
|
| 2015-03-25 |
股东大会：
将于2015-05-07召开股东大会
|
| 2015-02-04 |
除权日：
美东时间 2015-02-18 每股派息0.70美元
|
| 2014-11-24 |
股东大会：
将于2014-12-18召开股东大会
会议内容 ▼▲
- 1.THAT the proposed transaction by the Company with Novartis AG (“Novartis”) consisting of three inter-conditional components, being (i) the entry by the Company into, and the creation of, the Consumer Healthcare Joint Venture including the grant by the Company of the Novartis JV Put Option, (ii) the acquisition by the Company of Novartis’s Vaccines Business, and (iii) the divestment by the Company of the Oncology Business, together with (iv) the Influenza Put Option (each capitalised term being as defined in the circular sent to shareholders of the Company dated 20 November 2014), and being on the terms and subject to the conditions contained in the Implementation Agreement, the Contribution Agreement (including the Shareholders’ Agreement to be entered into pursuant thereto), the Vaccines SAPA, the Oncology SPA, the Influenza Put Option Deed (each capitalised term being as defined in the aforementioned circular) and the associated and ancillary agreements and arrangements relating thereto (the “Transaction”), be and is hereby approved for the purposes of Chapter 10 of the Listing Rules of the Financial Conduct Authority, and the Directors of the Company (or a duly authorised committee thereof) be and are hereby authorised to:
(i) take all such steps, execute all such agreements and make such arrangements as may seem to them necessary, expedient or desirable for the purpose of giving effect to, or otherwise in connection with, the Transaction and/or associated and ancillary arrangements relating thereto;
(ii) agree and make such modifications, variations, revisions, waivers or amendments in relation to any of the foregoing (provided that such modifications, variations, revisions, waivers or amendments are not material) as they may in their absolute discretion think necessary, expedient or desirable.
|
| 2014-11-24 |
股东大会：
将于2014-12-18召开股东大会
会议内容 ▼▲
- 1.THAT the proposed transaction by the Company with Novartis AG (“Novartis”) consisting of three inter-conditional components, being (i) the entry by the Company into, and the creation of, the Consumer Healthcare Joint Venture including the grant by the Company of the Novartis JV Put Option, (ii) the acquisition by the Company of Novartis’s Vaccines Business, and (iii) the divestment by the Company of the Oncology Business, together with (iv) the Influenza Put Option (each capitalised term being as defined in the circular sent to shareholders of the Company dated 20 November 2014), and being on the terms and subject to the conditions contained in the Implementation Agreement, the Contribution Agreement (including the Shareholders’ Agreement to be entered into pursuant thereto), the Vaccines SAPA, the Oncology SPA, the Influenza Put Option Deed (each capitalised term being as defined in the aforementioned circular) and the associated and ancillary agreements and arrangements relating thereto (the “Transaction”), be and is hereby approved for the purposes of Chapter 10 of the Listing Rules of the Financial Conduct Authority, and the Directors of the Company (or a duly authorised committee thereof) be and are hereby authorised to:
(i) take all such steps, execute all such agreements and make such arrangements as may seem to them necessary, expedient or desirable for the purpose of giving effect to, or otherwise in connection with, the Transaction and/or associated and ancillary arrangements relating thereto;
(ii) agree and make such modifications, variations, revisions, waivers or amendments in relation to any of the foregoing (provided that such modifications, variations, revisions, waivers or amendments are not material) as they may in their absolute discretion think necessary, expedient or desirable.
|
| 2014-10-22 |
除权日：
美东时间 2014-11-05 每股派息0.61美元
|
| 2014-07-23 |
除权日：
美东时间 2014-08-06 每股派息0.65美元
|
| 2014-04-30 |
除权日：
美东时间 2014-05-14 每股派息0.64美元
|
| 2014-02-05 |
除权日：
美东时间 2014-02-19 每股派息0.75美元
|
| 2013-10-23 |
除权日：
美东时间 2013-11-13 每股派息0.62美元
|
| 2013-07-24 |
除权日：
美东时间 2013-08-07 每股派息0.55美元
|
| 2013-04-24 |
除权日：
美东时间 2013-05-08 每股派息0.55美元
|
| 2013-02-06 |
除权日：
美东时间 2013-02-20 每股派息0.69美元
|
| 2012-10-31 |
除权日：
美东时间 2012-11-14 每股派息0.58美元
|
| 2012-07-25 |
除权日：
美东时间 2012-08-08 每股派息0.53美元
|
| 2012-04-25 |
除权日：
美东时间 2012-05-09 每股派息0.55美元
|
| 2012-02-07 |
除权日：
美东时间 2012-02-15 每股派息0.82美元
|
| 2011-10-26 |
除权日：
美东时间 2011-11-02 每股派息0.54美元
|
| 2011-07-26 |
除权日：
美东时间 2011-08-03 每股派息0.52美元
|
| 2011-04-27 |
除权日：
美东时间 2011-05-04 每股派息0.53美元
|
| 2011-02-03 |
除权日：
美东时间 2011-02-09 每股派息0.62美元
|
| 2010-10-21 |
除权日：
美东时间 2010-10-27 每股派息0.51美元
|
| 2010-07-22 |
除权日：
美东时间 2010-07-28 每股派息0.46美元
|